Summary: Net sales of Arzerra® for the first quarter of 2010 were approximately DKK 42 million, with an expected royalty payment to Genmab of DKK 8 million.

Genmab A/S (Copenhagen:GEN) announced today that the U.S. net sales for Arzerra (ofatumumab) during the first quarter of 2010 were approximately DKK 42 million (approximately USD 7.5 million).  Under the terms of the collaboration with GlaxoSmithKline (GSK) Genmab expects to receive a royalty payment of approximately DKK 8 million (approximately USD 1.4 million).

"We are pleased that Arzerra offers a new treatment option for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab, "likewise we are looking forward to this option being available in the EU as well."

Arzerra was granted accelerated approval by the FDA in October, 2009, for the treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in

mid-November, 2009. In April 2010, a conditional marketing authorization for the treatment of chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab was granted by the EU Commission.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties

related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com.  Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™; HuMax-Her2™; HuMax-VEGF™; HuMax-Wnt; HuMax-cMet™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

CONTACT:  Genmab A/S

          Helle Husted, Vice President, Investor Relations

          +45 33 44 77 30

          Mobile: +45 25 27 47 13

          h.husted@genmab.com